Form 4: Regeneron Director Poon Acquires Stock, Options

Regeneron Pharmaceuticals Director Christine A. Poon acquired 155 shares of common stock and 1,962 non-qualified stock options in a pre-planned transaction.

Summary

• Christine A. Poon, a Director of Regeneron Pharmaceuticals, Inc., acquired 155 shares of common stock.
• These shares represent time-based vesting restricted stock units.
• Poon also acquired 1,962 non-qualified stock options with an exercise price of $772.76.
• The options will become partially exercisable on the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder exercisable on the first anniversary of the grant date.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-planned.

Sentiment

Score: 7

Explanation: The filing reports a standard compensation grant to a director, increasing their stake and aligning interests with shareholders. This is generally viewed positively as a routine governance action.

Positives

• Director Christine A. Poon increased her beneficial ownership of Regeneron common stock by 155 shares, aligning her interests further with shareholders.
• The grant of 1,962 non-qualified stock options provides a long-term incentive for the director, with an exercise price of $772.76.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-planned and transparent acquisition.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing reports a standard insider transaction for director compensation, which is a common practice across the pharmaceutical industry to align management and director interests with shareholders. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• NA

Related Party Transactions

• The transaction involves a director of Regeneron Pharmaceuticals, Inc. acquiring company securities as part of their compensation package, which is a standard insider transaction.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by a director, through both common stock and stock options, can enhance alignment of interests between the director and shareholders, potentially leading to more shareholder-focused decision-making.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• A portion of the acquired stock options will become exercisable on the date of Regeneron's first annual meeting of shareholders following the grant date.
• The remainder of the stock options will become exercisable on the first anniversary of the grant date.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, Form 4, Insider Transaction, Stock Acquisition, Stock Options, Director Compensation, Christine A. Poon, Restricted Stock Units, 10b5-1 Plan